Feedback-Amplified Drug Delivery of αPD-L1-Modified Lipoplatin for Chronological Synergy in NSCLC through PD-L1 Upregulation
{{output}}
The limited efficacy of PD-L1 blockade in non-small cell lung cancer (NSCLC) patients with low PD-L1 expression necessitates the optimization of therapeutic strategies. In this study, we found that PD-L1 expression levels correlate with survival outcomes in α... ...
